GYRE
Price
$11.54
Change
-$1.02 (-8.12%)
Updated
Feb 21 closing price
Capitalization
991.25M
38 days until earnings call
MIST
Price
$2.04
Change
-$0.02 (-0.97%)
Updated
Feb 21 closing price
Capitalization
108.79M
37 days until earnings call
Ad is loading...

GYRE vs MIST

Header iconGYRE vs MIST Comparison
Open Charts GYRE vs MISTBanner chart's image
Gyre Therapeutics
Price$11.54
Change-$1.02 (-8.12%)
Volume$63.92K
Capitalization991.25M
Milestone Pharmaceuticals
Price$2.04
Change-$0.02 (-0.97%)
Volume$568.51K
Capitalization108.79M
GYRE vs MIST Comparison Chart
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. MIST commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and MIST is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (GYRE: $11.54 vs. MIST: $2.04)
Brand notoriety: GYRE and MIST are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 71% vs. MIST: 76%
Market capitalization -- GYRE: $991.25M vs. MIST: $108.79M
GYRE [@Biotechnology] is valued at $991.25M. MIST’s [@Biotechnology] market capitalization is $108.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileMIST’s FA Score has 0 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • MIST’s FA Score: 0 green, 5 red.
According to our system of comparison, both GYRE and MIST are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 6 TA indicator(s) are bullish while MIST’s TA Score has 1 bullish TA indicator(s).

  • GYRE’s TA Score: 6 bullish, 4 bearish.
  • MIST’s TA Score: 1 bullish, 6 bearish.
According to our system of comparison, GYRE is a better buy in the short-term than MIST.

Price Growth

GYRE (@Biotechnology) experienced а -3.67% price change this week, while MIST (@Biotechnology) price change was -10.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

GYRE is expected to report earnings on May 08, 2025.

MIST is expected to report earnings on May 19, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($991M) has a higher market cap than MIST($109M). GYRE YTD gains are higher at: -4.628 vs. MIST (-13.559). GYRE has higher annual earnings (EBITDA): 11.8M vs. MIST (-39.14M). MIST has more cash in the bank: 76.4M vs. GYRE (25.1M). GYRE has less debt than MIST: GYRE (1.8M) vs MIST (54M). GYRE has higher revenues than MIST: GYRE (105M) vs MIST (0).
GYREMISTGYRE / MIST
Capitalization991M109M909%
EBITDA11.8M-39.14M-30%
Gain YTD-4.628-13.55934%
P/E RatioN/AN/A-
Revenue105M0-
Total Cash25.1M76.4M33%
Total Debt1.8M54M3%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
PROFIT vs RISK RATING
1..100
73
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
47
P/E GROWTH RATING
1..100
4
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GYREMIST
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 12 days ago
83%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OPHLY3.410.06
+1.79%
Ono Pharmaceutical Co., Ltd.
NOKBF5.00N/A
N/A
Nokia Corp.
TSNDF0.53-0.01
-2.58%
TerrAscend Corp.
RYCEY7.73-0.21
-2.64%
Rolls Royce Holdings plc
RSNVF0.05N/A
-3.75%
Reyna Silver Corp.

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-8.12%
SPRC - GYRE
38%
Loosely correlated
-4.37%
KYMR - GYRE
31%
Poorly correlated
-1.63%
NAMS - GYRE
31%
Poorly correlated
-2.26%
ENGN - GYRE
31%
Poorly correlated
+2.78%
ADCT - GYRE
30%
Poorly correlated
-2.40%
More

MIST and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIST has been loosely correlated with CLDX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MIST jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIST
1D Price
Change %
MIST100%
-0.97%
CLDX - MIST
39%
Loosely correlated
-0.58%
KRYS - MIST
36%
Loosely correlated
+2.87%
MLTX - MIST
36%
Loosely correlated
+0.55%
RGNX - MIST
30%
Poorly correlated
-1.22%
GYRE - MIST
28%
Poorly correlated
-8.12%
More